Full-Time

ServiceNow Senior Manager

Posted on 5/23/2026

Deadline 6/30/26
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Global biopharma researching, developing, delivering medicines

Compensation Overview

$135.3k - $164k/yr

+ Incentive Cash + Stock Opportunities

Company Historically Provides H1B Sponsorship

Princeton, NJ, USA

In Person

On-site requirement: site-essential role; 100% onsite.

Category
IT & Security (1)
Required Skills
Agile
ServiceNow
Vulnerability Analysis
Risk Management
Requirements
  • Degree in Computer Science, Information Systems, related field, or equivalent work experience.
  • 8+ years of experience in IT Risk Management, Governance, Risk Management, and Compliance domains.
  • Excellent communication and collaboration abilities to work effectively with cross-functional teams.
  • Strong capability to operate in a techno-functional role, translating complex business needs into actionable Agile stories with precise acceptance criteria.
  • Proven proficiency in at least two of the following areas: Governance, Risk and Compliance, Security Operations, Third-Party Risk, Privacy, or Legal Service Delivery.
  • Proven ability to manage relationships with multiple stakeholders and work independently in a fast-paced environment.
  • Familiarity with vulnerability management processes and tools, such as Qualys and Wiz.
  • Experience with Privacy Management tools such as OneTrust or ServiceNow Privacy Management.
  • Experience leading platform migration or consolidation initiatives.
  • ServiceNow Certified System Administrator (CSA) or relevant Governance, Risk and Compliance certifications such as CRISC, CISA, or CISM.
  • Experience in the pharmaceutical, life sciences, or a similarly regulated industry.
Responsibilities
  • Independently lead initiatives end-to-end, acting as both the business partner and technical architect for ServiceNow solutions.
  • Gather business requirements and translate them into Agile stories with clear acceptance criteria for the offshore development team.
  • Design and architect scalable solutions within the ServiceNow platform across Governance, Risk and Compliance, Security Operations, and Legal Service Delivery modules.
  • Manage relationships with process owners across Governance, Risk and Compliance, Security Operations, and Legal Service Delivery, handling day-to-day escalations.
  • Partner with the OneTrust team to document current-state privacy workflows and translate them into ServiceNow Privacy Management requirements.
  • Ensure feature parity, capture acceptance criteria, and support knowledge transfer during platform migrations.
  • Coordinate User Acceptance Testing (UAT) with stakeholders and support change and release lifecycle management in ServiceNow.
  • Prepare and present delivery metrics to leadership, coordinate with vendors, and support resource planning.
  • Ensure clear communication and transparency within the team and stakeholders.
  • Identify opportunities for new/improved architecture opportunities.
  • Must be self-directed with proven ability to make mature decisions supported by thorough data and process analysis.

Bristol Myers Squibb develops and sells medicines for serious diseases, focusing on cancer, immune system disorders, and cardiovascular conditions. Its work starts with research and development to create new therapies, which are then approved by regulators before being used by doctors and patients; the company also offers generic versions and supports biosimilars to expand access. BMS differentiates itself with a broad portfolio of innovative medicines alongside affordable options and a strong emphasis on ESG and regulatory engagement. The goal is to improve patient health by delivering effective, affordable medicines and advancing sustainable healthcare globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Anthropic deployment across 30,000 employees can streamline research, development, and manufacturing workflows.
  • Tempus AI collaboration targets faster trial design and higher technical success across five programs.
  • Hengrui partnership adds 13 programs and externalizes early development to speed proof-of-concept work.

What critics are saying

  • Eliquis and Opdivo face patent-cliff exposure, threatening major revenue declines after 2028.
  • Heavy dependence on a few products leaves earnings vulnerable to pricing, volume, and exclusivity shocks.
  • AI and China outsourcing expand operational complexity, compliance risk, and partner dependency.

What makes Bristol Myers Squibb unique

  • BMS owns blockbuster drugs Eliquis, Opdivo, and Revlimid across oncology and cardiovascular care.
  • Its core mission emphasizes discovering, developing, and delivering innovative medicines for serious diseases.
  • BMS combines global research, manufacturing, and commercial scale with broad therapeutic expertise.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Bristol Myers Squibb who can refer or advise you

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-4%
Pharma Focus Asia
May 21st, 2026
Bristol Myers Squibb enters into agreement with Anthropic for AI deployment across global operations.

Bristol Myers Squibb enters into agreement with Anthropic for AI deployment across global operations. Thursday, May 21, 2026 Bristol Myers Squibb has entered into a strategic agreement with Anthropic to deploy Claude Enterprise across its global operations. The partnership aims to strengthen the use of artificial intelligence in research, clinical development, manufacturing, commercial activities, and corporate functions. The company plans to provide Claude's AI capabilities to more than 30,000 employees. The initiative is designed to move beyond basic chatbot applications and introduce agentic AI systems that can support everyday workflows and decision-making across the organisation. As part of the agreement, Bristol Myers Squibb will use Claude Code to support engineering and data science teams in accelerating software and AI development. The company expects this approach to improve the integration of data and expertise currently spread across disconnected systems. The collaboration will also focus on embedding AI agents into key pharmaceutical workflows. In research, AI tools will be used to analyse scientific, molecular, and clinical data to support target identification and optimisation in areas including oncology, haematology, neuroscience, and immunology. In drug development, the company plans to apply intelligent automation to activities such as preparing clinical study reports, patient safety narratives, and regulatory submissions. The aim is to reduce the time required between clinical data completion and regulatory filing. Manufacturing and quality operations will also benefit from AI-driven support for root-cause investigations, corrective and preventive action documentation, and batch release decisions. The company expects these improvements to strengthen compliance, speed up decision-making, and support faster medicine delivery. In commercial and medical affairs, the technology will help organise field insights into structured information to improve engagement with healthcare professionals and deliver more relevant information when needed. Claude will also be connected to internal systems and repositories containing scientific, clinical, regulatory, and commercial knowledge. Bristol Myers Squibb stated that the deployment will operate with enterprise governance and audit controls. The agreement builds on more than three years of AI investment by Bristol Myers Squibb. The company has already provided employees with access to multiple frontier AI models through its internal AI platform as part of a broader multi-vendor strategy.

360Dx
Apr 21st, 2026
In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion.

In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion. NEW YORK - Foundation Medicine said Tuesday that it has expanded an ongoing collaboration with Bristol Myers Squibb to develop FoundationOne CDx as a next-generation sequencing-based companion diagnostic to identify patients with homozygous MTAP deletion in multiple indications for an investigational targeted therapy. Get the full story with 360dx Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month

Yahoo Finance
Apr 13th, 2026
Bristol Myers Squibb: 4.2% dividend yield and stable revenue at bargain valuation

Bristol Myers Squibb presents an attractive value investment in the pharmaceutical sector, with a forward price-to-earnings ratio of 9.5, significantly lower than competitors Johnson & Johnson (21) and Merck (24). The company offers a 4.2% dividend yield and has increased payouts for 17 consecutive years. Bristol reported $48.2 billion in revenue for 2025, with 2026 guidance between $46 billion and $47.5 billion, demonstrating consistency despite modest decline. However, the favourable valuation reflects investor concerns about slowing legacy portfolio revenue, which fell from $25.7 billion in 2024 to $21.8 billion in 2025. Key challenges include an upcoming patent cliff for Eliquis, its blood thinner generating $14.4 billion in 2025 sales, and the $1.5 billion acquisition of Orbital Therapeutics whilst carrying over $47 billion in debt.

Yahoo Finance
Apr 10th, 2026
Bristol Myers' Cobenfy hits $155M in first year, outpacing rival schizophrenia treatments

Bristol Myers Squibb's schizophrenia drug Cobenfy generated $155 million in sales during 2025, outpacing comparable treatments in its first year following FDA approval in September 2024. The medication represents the first new pharmacological approach to treating schizophrenia in decades. Recent phase II data presented at the Schizophrenia International Research Society Annual Congress showed adults with schizophrenia remained stable after switching to Cobenfy monotherapy over eight weeks, with low discontinuation rates and no dropouts due to lack of efficacy. Bristol Myers is pursuing label expansions across multiple indications, with ongoing phase III studies in Alzheimer's disease psychosis, agitation, cognitive impairment, bipolar I disorder and paediatric irritability associated with autism. The company expects Cobenfy to become a significant growth driver as legacy drugs face generic competition.

Buzzword News
Mar 30th, 2026
Bristol Myers Squibb adding 3 medications on TrumpRx.

Bristol Myers Squibb adding 3 medications on TrumpRx. Mar 30, 2026 - 14:01 EXCLUSIVE: Bristol Myers Squibb is launching three medications on TrumpRx.gov on Monday, FOX Business has learned. The three prescription drugs will each be offered at deep discounts that range from 40% to 90% off the retail price. The Princeton, New Jersey-based company's drug Sotyktu retails for $7,135.55 and will be offered through TrumpRx.gov for $743. That represents a 90% discount off what patients have been paying. Sotyktu treats adults with moderate-to-severe plaque psoriasis. Zeposia, which treats relapsing forms of multiple sclerosis, will be added at a discount of between 88% and 90%. The weekly injection to treat moderate-to-severe rheumatoid arthritis, Orencia SC, will be reduced by 40% from the retail price. A White House official said this is the latest big pharma company to offer reduced prices after the tariff pressure from President Donald Trump. The talks with pharmaceutical companies continue to be successful, with more medications added to the government website. Bristol Myers' additions come weeks after FOX Business reported that Amgen and GSK were added to the list of prescription drug manufacturers offering discounts on the government website. Amgen offers medications on the website that cut 80% off the retail price. Amjevita has an original price of $1,484, but will be available on TrumpRx.gov for $299. The medication treats rheumatoid arthritis, psoriasis and ulcerative colitis. Amgen also lists Aimovig and Repatha for discounts of 62%. GSK discounts Incruse at 55% off the retail price. The drug treats COPD and will be listed at $159.20. GSK lists Arnuity, Relenza and Anoro at discounts ranging from 10% to 51%. The White House is pushing ahead with announcements to TrumpRx.gov as Americans look for ways to cut medical costs. Under the Biden administration, Bureau of Labor Statistics data shows, prescription drug costs increased 10.4% from January 2021 to January 2025. Under the Trump administration, prescription drug prices increased 0.2% from January 2025 through the latest data from February 2026.